目的:评价静脉内和冠脉内同时应用负荷剂量替罗非班在急性ST段抬高心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)中的疗效和安全性。方法:43例拟行急诊PCI术STEMI患者随机选入替罗非班IV组(仅静脉内推注负荷剂量替罗非班,22例)和...目的:评价静脉内和冠脉内同时应用负荷剂量替罗非班在急性ST段抬高心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)中的疗效和安全性。方法:43例拟行急诊PCI术STEMI患者随机选入替罗非班IV组(仅静脉内推注负荷剂量替罗非班,22例)和替罗非班IV&IC组(静脉内和冠脉内同时推注负荷剂量替罗非班,21例),观察患者PCI术前术后thrombolysis in myocardial infarction trial(TIMI)血流分级和心肌组织灌注,住院期间心脏超声、主要不良心血管事件(MACE)、出血事件和血小板减少,以及术后30d的MACE。结果:两组患者的基础临床情况和术前冠脉造影特征差异无统计学意义;两组患者术后TIMI血流分级,校正的TIMI帧数计数(CTFC)≤27帧差异无统计学意义;术后心电图ST段抬高总和回落(sumSTR)百分比≥70%,肌钙蛋白I(cTnI)与肌酸激酶同工酶(CK-MB)峰值浓度等差异无统计学意义;住院期间左室收缩功能、MACE、大量出血事件、血小板减少症的发生率等差异无统计学意义;两组术后30dMACE发生率差异无统计学意义。结论:在STEMI患者急诊PCI术中,静脉内和冠脉内同时应用负荷剂量替罗非班是安全的,近期疗效与单纯静脉内应用替罗非班相当。展开更多
Objectives. To estimate the anti- tumor activity, nature and degree of toxicity of tirapazamine in combination with cisplatin in patients with recurrent platinum- sensitive ovarian or primary peritoneal cancers. Metho...Objectives. To estimate the anti- tumor activity, nature and degree of toxicity of tirapazamine in combination with cisplatin in patients with recurrent platinum- sensitive ovarian or primary peritoneal cancers. Methods. Eligible consenting patients had to have recurrent epithelial ovarian or primary peritoneal carcinoma with measurable disease. Patients were not allowed to have received any additional cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens. Patients must have been platinum- sensitive, meaning a treatment- free interval of >6 months after response to a platinum- based regimen. The RECIST criteria were used for parameters of response. Tirapazamine was administered at a dose of 390 mg/m2 IV over 2 h followed 1 h later by cisplatin 60 mg/m 2 IV every 3 weeks until disease progression or adverse effects prohibited further therapy. Results. Between June 2001 and February 2004, 65 patients were entered onto this study by 27 institutions; one patient was excluded due to ineligible tumor type. Twenty- six patients (41% ) received six or more cycles of therapy; however, 16 (25% ) received one course of therapy (mainly due to side effects or patient request). There were six (9% ) complete responders and 28 (44% ) partial responders for a total response rate of 53% . Only two patients (3% ) developed increasing disease on this protocol, and response could not be assessed in 18 patients (28% ). The median progression- free and overall survival for all patients is 10.9 and 26.4 months, respectively. The regimen did not cause major hematologic toxicity,however, it did cause frequent constitutional (23% ) and gastrointestinal (mostly nausea/vomiting) (44% ) grade 3 or 4 toxicity. Conclusions. The combination of tirapazamine and cisplatin has definite activity in the treatment of recurrent platinum- sensitive ovarian or primary peritoneal cancer. However, toxicity, primarily non- hematologic,was substantial. Reducing the toxicity of a tir展开更多
文摘目的:评价静脉内和冠脉内同时应用负荷剂量替罗非班在急性ST段抬高心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)中的疗效和安全性。方法:43例拟行急诊PCI术STEMI患者随机选入替罗非班IV组(仅静脉内推注负荷剂量替罗非班,22例)和替罗非班IV&IC组(静脉内和冠脉内同时推注负荷剂量替罗非班,21例),观察患者PCI术前术后thrombolysis in myocardial infarction trial(TIMI)血流分级和心肌组织灌注,住院期间心脏超声、主要不良心血管事件(MACE)、出血事件和血小板减少,以及术后30d的MACE。结果:两组患者的基础临床情况和术前冠脉造影特征差异无统计学意义;两组患者术后TIMI血流分级,校正的TIMI帧数计数(CTFC)≤27帧差异无统计学意义;术后心电图ST段抬高总和回落(sumSTR)百分比≥70%,肌钙蛋白I(cTnI)与肌酸激酶同工酶(CK-MB)峰值浓度等差异无统计学意义;住院期间左室收缩功能、MACE、大量出血事件、血小板减少症的发生率等差异无统计学意义;两组术后30dMACE发生率差异无统计学意义。结论:在STEMI患者急诊PCI术中,静脉内和冠脉内同时应用负荷剂量替罗非班是安全的,近期疗效与单纯静脉内应用替罗非班相当。
文摘Objectives. To estimate the anti- tumor activity, nature and degree of toxicity of tirapazamine in combination with cisplatin in patients with recurrent platinum- sensitive ovarian or primary peritoneal cancers. Methods. Eligible consenting patients had to have recurrent epithelial ovarian or primary peritoneal carcinoma with measurable disease. Patients were not allowed to have received any additional cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens. Patients must have been platinum- sensitive, meaning a treatment- free interval of >6 months after response to a platinum- based regimen. The RECIST criteria were used for parameters of response. Tirapazamine was administered at a dose of 390 mg/m2 IV over 2 h followed 1 h later by cisplatin 60 mg/m 2 IV every 3 weeks until disease progression or adverse effects prohibited further therapy. Results. Between June 2001 and February 2004, 65 patients were entered onto this study by 27 institutions; one patient was excluded due to ineligible tumor type. Twenty- six patients (41% ) received six or more cycles of therapy; however, 16 (25% ) received one course of therapy (mainly due to side effects or patient request). There were six (9% ) complete responders and 28 (44% ) partial responders for a total response rate of 53% . Only two patients (3% ) developed increasing disease on this protocol, and response could not be assessed in 18 patients (28% ). The median progression- free and overall survival for all patients is 10.9 and 26.4 months, respectively. The regimen did not cause major hematologic toxicity,however, it did cause frequent constitutional (23% ) and gastrointestinal (mostly nausea/vomiting) (44% ) grade 3 or 4 toxicity. Conclusions. The combination of tirapazamine and cisplatin has definite activity in the treatment of recurrent platinum- sensitive ovarian or primary peritoneal cancer. However, toxicity, primarily non- hematologic,was substantial. Reducing the toxicity of a tir
